Lupin Ltd. Sees Significant Open Interest Surge Amid Bullish Momentum

Open Interest and Volume Dynamics

The latest data reveals that Lupin’s open interest in derivatives rose sharply to 26,668 contracts, up 15.85% from the previous 23,019 contracts. This increase of 3,649 contracts indicates a substantial build-up of positions, suggesting that market participants are actively positioning themselves ahead of anticipated price movements. Concurrently, the volume stood at 26,480 contracts, closely tracking the open interest, which underscores robust trading activity in the stock’s futures and options segments.

In monetary terms, the futures segment recorded a value of approximately ₹36,600 lakhs, while the options segment exhibited an enormous notional value of ₹22,110 crores, culminating in a total derivatives value of ₹41,293 lakhs. Such elevated figures highlight the stock’s liquidity and attractiveness for derivative traders, enabling sizeable trades without significant market impact.

Price Performance and Technical Indicators

Lupin’s underlying price has demonstrated resilience, outperforming its sector by 1.16% on the day and registering a 0.68% gain compared to the Sensex’s decline of 0.59%. The stock has been on a three-day consecutive gain streak, delivering a cumulative return of 3.65% during this period. Notably, Lupin is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong uptrend and positive technical momentum.

The intraday high of Rs 2,244.5 marks a fresh 52-week peak, reinforcing the bullish narrative. However, delivery volumes have seen a slight dip, with 5.31 lakh shares delivered on 4 February, down 7.04% against the five-day average. This decline in delivery volume suggests that while short-term speculative interest is rising, longer-term investor participation remains cautious.

Market Positioning and Directional Bets

The surge in open interest alongside rising prices and volumes points to an accumulation phase by market participants, likely anticipating further upside. The 15.85% increase in OI is significant in the context of Lupin’s large-cap status and ₹1,00,752 crore market capitalisation, indicating that institutional and retail traders alike are increasing their exposure.

Given the stock’s outperformance relative to its sector and benchmark indices, the directional bias appears bullish. The futures value of ₹36,600 lakhs and the massive options notional value suggest active hedging and speculative strategies, with traders possibly favouring call options to capitalise on expected gains. The elevated OI in options also hints at increased open positions in both calls and puts, reflecting a complex interplay of bullish and protective strategies.

However, the slight decline in delivery volumes signals that some investors may be adopting a wait-and-watch approach, preferring to trade derivatives rather than take outright delivery. This dynamic often precedes significant price moves, as derivative positioning can amplify volatility in the underlying stock.

Mojo Score and Analyst Ratings

Lupin currently holds a Mojo Score of 74.0 with a Mojo Grade of Buy, recently downgraded from a Strong Buy on 28 January 2026. This adjustment reflects a cautious stance amid the recent price rally, suggesting that while fundamentals remain robust, valuations may be approaching a level warranting prudence. The Market Cap Grade of 1 confirms Lupin’s status as a large-cap stock with substantial market presence and liquidity.

Analysts note that Lupin’s consistent execution and strong fundamentals underpin its positive outlook, but the recent surge in derivatives activity calls for close monitoring of market sentiment and potential volatility. Investors should weigh the technical strength against the possibility of short-term corrections following the sharp price appreciation.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector has been under pressure recently, with the sector index declining 0.48% on the day. Lupin’s outperformance against this backdrop highlights its relative strength and investor preference. The company’s large-cap status and strong liquidity profile, with a tradable size of approximately ₹3.93 crore based on 2% of the five-day average traded value, make it an attractive option for both institutional and retail traders seeking exposure to the sector.

Moreover, Lupin’s ability to sustain gains above all major moving averages indicates a healthy technical setup, which could attract momentum-driven investors. However, the sector’s overall weakness suggests that broader market factors, such as regulatory developments or global pharmaceutical trends, may influence Lupin’s trajectory in the near term.

Investor Takeaway

For investors and traders, the recent surge in Lupin’s open interest and volume signals heightened interest and potential for further price discovery. The combination of strong technical indicators, positive relative performance, and increased derivatives activity suggests that Lupin is currently in a favourable position to continue its upward trend.

Nonetheless, the downgrade from Strong Buy to Buy and the dip in delivery volumes warrant a measured approach. Investors should consider monitoring open interest changes closely, as sudden spikes can precede volatility. Those with a bullish outlook may look to participate through futures or call options, while more cautious investors might await confirmation of sustained price momentum before increasing exposure.

Overall, Lupin Ltd. remains a compelling large-cap stock within the Pharmaceuticals & Biotechnology sector, supported by solid fundamentals and active market positioning, but investors should remain vigilant to evolving market dynamics.

Unlock special upgrade rates for a limited period. Start Saving Now →